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Similar pathophysiological mechanisms within autoimmune diseases have stimulated searches for common genetic roots.
Polyautoimmunity is defined as the presence of more than one autoimmune disease in a single patient. When three or more
autoimmune diseases coexist, this condition is called multiple autoimmune syndrome (MAS). We analyzed the presence of
polyautoimmunity in 1,083 patients belonging to four autoimmune disease cohorts. Polyautoimmunity was observed in 373
patients (34.4%). Autoimmune thyroid disease (AITD) and Sjo¨gren’s syndrome (SS) were the most frequent diseases encountered.
Factors significantly associated with polyautoimmunity were female gender and familial autoimmunity. Through a systematic
literature review, an updated search was done for all MAS cases (January 2006–September 2011). There were 142 articles retrieved
corresponding to 226 cases. Next, we performed a clustering analysis in which AITD followed by systemic lupus erythematosus and
SS were the most hierarchical diseases encountered. Our results indicate that coexistence of autoimmune diseases is not uncommon
and follows a grouping pattern. Polyautoimmunity is the term proposed for this association of disorders, which encompasses the
concept of a common origin for these diseases.
1. Introduction
Autoimmune diseases (ADs) have particular clinical char-
acteristics and phenotypes depending on their nature (i.e.,
organ specific or systemic diseases). However, there is strong
evidence that ADs share several clinical signs and symptoms,
physiopathological mechanisms, and environmental and
genetic factors, and this fact indicates that they have a
common origin [1], which has been called the autoimmune
tautology.
The clinical evidence of the autoimmune tautology
highlights the cooccurrence of distinct ADs within an indi-
vidual (i.e., polyautoimmunity) [1]. In an earlier paper, we
described the foremost systematic literature review grouping
all published cases of multiple autoimmune syndromes
(MAS), defined by the presence of three or more well-
defined ADs in a single patient, up until 2006. Initially,
MAS was first mentioned by Pirofsky and Vaughn [2]
and deeply described by Humbert and Dupond [3]. They
provided a taxonomy for the cooccurrent phenotypes [4, 5].
MAS together with polyglandular autoimmune syndromes
(PAS) II through IV, which are all MAS, represent the
best example of polyautoimmunity [4]. Three basic, large
clusters were found. Each of them had a predominant disease
that was named the “chaperones” of autoimmunity, namely,
autoimmune thyroid disease (AITD), Sjo¨gren’s syndrome
(SS), and systemic lupus erythematosus (SLE). Study of the
literature and clinical observation led to a similar clustering
nomenclature which included the thyrogastric cluster and
lupus-associated cluster [6, 7].
This coexistence of ADs in a single individual has lead
researchers to consider diﬀerent terms like autoimmune
diathesis [8] or kaleidoscope of autoimmunity [9] both of
which point to a common genetic background of ADs [10,
11]. The genetic basis of autoimmune clustering can depict
part of the patterns of clustering across the spectrum of the
implicated diseases [6].
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Polyautoimmunity is also important for the current
discussion because it may influence on the severity of ADs.
In fact, some authors argue that there is a more severe
presentation of a particular AD when polyautoimmunity is
present [12–14], while others have found no influence or
even a better prognosis in such cases [15–17].
In order to demonstrate one of the edges of autoimmune
tautology, this study describes the presence of polyautoim-
munity in four cohorts of ADs and analyses the main factors
associated with its presence. In addition, an update of MAS
cases is presented.
2. Material andMethods
2.1. Study Subjects. Four previously published series of ADs
patients were evaluated. All of them had cross-sectional
designs analyzing the presence of polyautoimmunity in
patients with SLE [18], rheumatoid arthritis (RA) [19], mul-
tiple sclerosis (MS) [20], and systemic sclerosis (SSc) [21].
All the patients were recruited from a multicenter cohort
of ADs patients followed at the Center for Autoimmune
Diseases Research (CREA) at the Universidad del Rosario in
Bogota, Colombia. Patients fulfilled the American College of
Rheumatology (ACR) criteria for the classification of SLE,
SSc, and RA [22–24] and McDonald’s criteria for MS [25].
The institutional review board approved the study design.
Each patient was evaluated by a rheumatologist or a
neurologist depending on the case. The information on
patient demographics and cumulative clinical and laboratory
data was obtained by physical examination, interview, and
chart review. All data were collected in an electronic and
secure database.
There were 23 ADs investigated in the cohorts based
on international validated criteria including autoimmune
adrenal insuﬃciency (AAI: Addison’s disease), alopecia
areata (AA), autoimmune hepatitis (AIH), AITD, antiphos-
pholipid syndrome (APS), biliary inflamatory disease includ-
ing primary sclerosing cholangitis and primary biliary
cirrhosis (BID), celiac disease (CD), demyelinating autoim-
mune diseases (DAD) including transverse myelitis (TM)
and MS, dermatomyositis, polymyositis (DM/PM), inflam-
atory bowel disease including ulcerative colitis and Crohn
disease (IBD), myastenia gravis (MG), pernicious anemia
(PA), pemphigus (PF), psoriasis (Pso), RA, relapsing poly-
chondritis (RePo), sarcoidosis (Sar), SS, SSc, SLE, type 1
diabetes mellitus (T1D), vasculitis (Vas), and vitiligo (VIT).
The presence of familial autoimmunity, including the
presence of the same group of ADs evaluated in the search
for polyautoimmunity, was estimated by interviewing the
patients and, in most of the cases, by clinical evaluation of the
aﬀected family members as previously reported [26]. First-
degree relatives (FDR) were defined as parents and siblings.
2.2. Systematic Literature Review. An updated systematic
literature review was done for all MAS cases reported from
January 2006 to September 2011 (Figure 1). Publications
were identified through a systematic search done by two
independent experts in Pubmed. The only limits applied
were Human. The [Majr] terms “multiple autoimmune
diseases,” “multiple autoimmune syndrome,” “multiple auto-
immune disease,” “polyautoimunity,” “co-occurrent,” “co-
occurrence,” “coexistence,” “overlap,” “associated,” “concur-
rent”; [Mesh] terms: diabetes mellitus, type 1; antiphos-
pholipid syndrome; lupus erythematosus, systemic; arthritis,
rheumatoid; arthritis, juvenile rheumatoid; arthritis, psori-
atic; spondylitis, ankylosing; spondylarthropathies; Sjo¨gren’s
syndrome; Churg-Strauss syndrome; giant cell arteritis;
microscopic polyangiitis; cryoglobulinemia; polyarteritis
nodosa; Wegener granulomatosis; scleroderma, localized;
scleroderma, systemic; scleroderma, diﬀuse; scleroderma,
limited; dermatomyositis; colitis, ulcerative; Crohn dis-
ease; inflammatory bowel diseases; anemia, pernicious; thy-
roiditis, autoimmune; Hashimoto disease; Graves disease;
celiac disease; hepatitis, autoimmune; liver cirrhosis, biliary;
cholangitis, sclerosing; myasthenia gravis; multiple sclero-
sis; myelitis, transverse; polychondritis, relapsing; Addison’s
disease; purpura, thrombocytopenic, idiopathic; psoriasis;
sarcoidosis; autoimmune gastritis; alopecia areata; autoim-
mune pancreatitis; pemphigus vulgaris; pemphigus bulloso;
pemphigus foliaceous; vitiligo; autoimmune anemia.
Finally, the systematic literature review up to 2006 was
checked and updated. The previous and new cases were
compiled into a new table (see Supplementary Material
available online at doi:10.1155/2012/254319).
2.3. Statistical Analysis. The prevalence of coexisting ADs
was figured out separately by individual. The diﬀerence in
the proportion of the associated ADs between two index
conditions was calculated by chi-square, multinomial test
corrected by Yate’s continuity depending on the case. The
degrees of freedom and Cramer’s V were calculated.
A multivariate analysis was done for each of the series
(SLE, MS, SSc, and RA) to identify factors associated
with polyautoimmunity using logistic regressions models
adjusted for age, gender, and duration of disease. Adjusted
odds ratios (AORs) were calculated with 95% confidence
intervals (CIs). A P value of less than 0.05 was considered
significant. The Hosmer and Lemeshow Goodness-of-Fit
Test was applied [27].
A hierarchical cluster procedure analysis was done to
identify relatively homogeneous subgroups of variables based
on selected cases with MAS reported in the systematic review
of the literature. The reported cases from the previous
systematic review [4] were computed with the results of the
updated search. The objective of this analysis was to find
out which ADs agglomerate more frequently. The cluster
method implemented [28] was Single Linkage Sneath and
the measure of similarity was Matching Coeﬃcient. SPSS
(V17 for Windows, Chicago, IL) software was used for all the
analysis.
3. Results
3.1. Polyautoimmunity Patients. The 1,083 individuals stud-
ied included 335 SLE, 304 RA, 154 MS, and 290 SSc patients.
There were 373 patients with polyautoimmunity (34.4%).
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142 articles with clinical descriptions
(case report or studies) were included
226 cases of MAS were
included
More than 10,000 articles were
excluded based on title or abstract
because they did not have information
about 3 or more ADs in the same
individual
9,860 articles were excluded bec use
they did not have complete
or more ADs, the MAS was defined
in the same individuals were not
correctly defined
There were 20,000 potential articles
of the terms used for 36 ADs [MeSH terms] and
up until September 2011
criteria for 3
with only 2 diseases, or the 3 or more ADs
with “autoimmune diseases” and each one
“concurrent,” “co-occurrent” “co-occurrence,”
“overlap,” “associated,” “coexistence,” “multiple
autoimmune syndrome,” “multiple autoimmune
disease,” “multiple autoimmune diseases,”
“concurrent,” and “polyautoimmunity” in Pubmed
a
Figure 1: Flow chart of the systematic literature review. ADs: autoimmune diseases; MAS: multiple autoimmune syndrome.
The prevalence of polyautoimmunity was significantly dif-
ferent among the four ADs, being less frequent in MS
(Table 1).
AITD was the most frequent coexisting AD and was
associated with SSc in 23% (N = 67) of the cases, RA
in 21% (N = 64), SLE in 17.9% (N = 60), and MS
in 9.1% (N = 14). This was followed by SS which was
associated with SSc in 14.8% (N = 43) of the cases, SLE
in 14% (N = 47), RA in 11.8% (N = 36), and MS in
2.6% (N = 4). MAS was found in 11.6% (N = 39),
9.7% (N = 28), 5.3% (N = 16), and 1.9% (N = 3) of SLE,
SSc, RA, and MS patients, respectively.
Factors significantly associated with polyautoimmunity
are depicted in Table 2. Female gender was a shared factor
that was significantly associated with polyautoimmunity
in the four ADs. Familial autoimmunity was significantly
associated with polyautoimmunity in SLE and SSc patients.
3.2. Systematic Literature Review. The flow chart for the
systematic literature review and the articles included are
shown in Figure 1. A total of 142 articles corresponding to
226 cases of MAS were included.
According to the dendogram (Figure 2), the most hier-
archical AD in the MAS cases is represented by AITD
followed by SLE and SS. Otherwise, the least representative
diseases in the same context are juvenile chronic arthritis
(JCA), ankylosing spondylitis (AS), and RePo. Although
there were several articles about combined AIH and BID
polyautoimmunity, the two were not close to each other
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Table 1: Polyautoimmunity in 1,083 patients with four index autoimmune diseases.
SLE RA MS SSc
chi df P Cramer’s V
N % N % N % N %
N 335 30.9 304 28.1 154 14.2 290 26.8
Polyautoimmunity 136 40.6 98 32.2 21 13.6 118 40.7 40.81 3 0.001 0.19
AITD 60 17.9 64 21.1 14 9.1 67 23.1 14.63 3 0.0022 0.11
SS 47 14.0 36 11.8 4 2.6 43 14.8 16.4 3 0.0009 0.12
VIT 2 1.3
APS 48 14.3 8 2.6 25.83 1 0.001∗ 0.2
Primary biliary cirrosis 15 5.2 — — — —
MAS 39 11.6 16 5.3 3 1.9 28 9.7 17.99 3 0.0004 0.12
SLE: systemic lupus erythematosus; RA: rheumatoid arthritis; MS: multiple sclerosis; SSc: systemic sclerosis; AITD: autoimmune thyroid disease; SS: Sjo¨gren’s
syndrome; VIT: vitiligo; APS: antiphospholipid syndrome; MAS: multiple autoimmune syndrome; chi: chi-square test; df: degree freedom; P: P value; ∗Yates
chi-square.
Table 2: Significant factors associated with polyautoimmunity.
SLE RA MS SSc
AOR; CI95% P AOR; CI95% P AOR; CI95% P AOR; CI95% P
Female gender 2.3; 1.03–5.15 0.043 1.8; 1.22–6.31 0.015 8.5; 1.02–70.8 0.048 9.08; 2.09–39.3 0.003
Familial autoimmunity 1.61; 1.14–2.28 0.007 NS NS 2.62; 1.24–5.54 0.01
Articular Involvement 2.02; 1.26–3.23 0.003 NS NE NS
Anti-Ro positivity 1.54; 1.10–2.16 0.013 NS NE NS
Cardiovascular disease NS 2.2; 1.17–3.94 0.014 NE NE
ANAs NS 2.0; 1.08–3.84 0.027 NS
SSEP NE NE 10.86; 1.31–89.6 0.027 NE
SLE: systemic lupus erythematosus; RA: rheumatoid arthritis; MS: multiple sclerosis; SSc: systemic sclerosis; AOR: adjusted odd ratio; CI95%: confidence
interval; ANAs: antinuclear antibodies; SSEP: somatosensory evoked potentials; NS: nonsignificant; NE: not evaluated.
on the dendogram nor did they show a suitable degree of
agreement.
4. Discussion
Herein, we report one of the largest series of polyautoim-
munity with an emphasis on its associated factors. Some
authors had shown that so far the evidence suggesting that
ADs tend to coexist within both individuals and families
was anecdotal corresponding to the concept of autoimmune
diathesis [29]. By grouping diverse ADs in the same patient
(i.e., polyautoimmunity) including organ specific (i.e., MS)
and systemic ADs, we have demonstrated that they are true
associations as a part of the autoimmune tautology rather
than the chance findings that were previous hypothesized
[4].
Polyautoimmunity is a term that can group all the
taxonomy terms referring to coexistence of well-defined ADs
in a single individual because some of the terms previously
used are confusing and exclude various associations. Polyau-
toimmunity was used by Sheenan and Stanton-King [30]
for the first time while describing a patient with ITP, PA,
AITD, SSc, pancreatic exocrine insuﬃciency, and CD before
dying from vasculitic complications. The case they depicted
corresponds to a typical MAS, which is already included
in the term polyautoimmunity. Also, when patients fully
develop two or more diseases simultaneously or sequentially,
these diseases have frequently been classified as overlap
syndromes; some of these were frequent enough to have been
given names like rhupus and sclerodermatomyositis [31].
In another case, some authors have historically postulated
that mixed connective tissue disease (MCTD) is a very
homogeneous entity with shared clinical manifestations
rather than shared diseases or autoantibodies [32, 33], while
others have not. The existence of MCTD as a distinct disease
entity has been a matter of controversy among researchers
since it was first described [34, 35]. In fact, the coexistence
of several sets of classification criteria for MCTD indicates
how diﬃcult it is to give a precise definition of the disease
[33]. In addition, some patients will develop SLE, SSc, or RA,
during the course of MCTD, and some will present with a
longstanding MCTD [36]. In real-life conditions, searching
for the specific phenotypes (antibodies and clinical) over the
course of disease and constantly looking for associated ADs,
including organ specific and systemic, are more useful for
developing an exact description of polyautoimmunity than
taxonomic discussions.
The fact that many ADs share a similar underlying
pathology and have a tendency to cluster supports the
involvement of shared susceptibility genes and similar
molecular mechanisms. In fact, recent studies have identified
several common genes associated with multiple ADs sup-
porting the presence of autoimmunity genes as part of the
autoimmune tautology [10, 37, 38].
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Figure 2: Cluster analysis dendogram. Each node represets a stage from the clustering process. There were four clusters. The most
hierarchical was composed of four ADs. AITD: autoimmune thyroid disease (including thyroiditis, Hashimoto disease, Graves disease); SLE:
systemic lupus erythematosus; SS: Sjo¨gren’s syndrome; APS: antiphospholipid syndrome; T1D: type 1 diabetes mellitus; SSc: scleroderma
(including localized, systemic, diﬀuse, limited); BID: billiary inflammatory disease (including primary biliary cirrhosis, primary sclerosing
cholangitis); CD: celiac disease; VIT: vitiligo; AIH: autoimmune hepatitis; RA: rheumatoid arthritis; MG: myasthenia gravis; PMDM:
polymyositis/dermatomyositis; PA: pernicious anemia; DAD: demyelinating autoimmune diseases (including multiple sclerosis, transverse
myelitis, optic neuromyelitis); AAI: autoimmune adrenal insuﬃciency (Addison disease); HA: autoimmune anemia; ITP: idiopathic
thrombocytopenic purpura; AG: autoimmune gastritis; VAS: vasculitis (including Churg-Strauss syndrome, giant cell arteritis, microscopic
polyangiitis, cryoglobulinemia, polyarteritis nodosa, Wegener granulomatosis); PF: pemphigus (including vulgaris, bulloso, foliaceous); IBD:
inflammatory bowel disease (including ulcerative colitis, Crohn’s disease); AA: alopecia areata; PsA: psoriasis (including psoriatic arthritis);
SAR: sarcoidosis; JCA: juvenile chronic arthritis; AS: ankylosing spondylitis; RePo: relapsing polychondritis.
Familial autoimmunity and female gender were con-
firmed as risk factors for polyautoimmunity. Female gender
was a shared factor associated with polyautoimmunity in
the four index conditions here studied. This fact gives us a
glimpse of one facet of the shared commonalities between
ADs. The majority of ADs predominate in females [39] and
constitute a leading cause of death among young and middle-
aged women [40]. In searching for a reason behind female
predominance, most attention has focused on hormonal
changes while other factors have included genetic diﬀerences,
both direct (i.e., influence of genes on sex chromosomes)
and indirect such as microchimerism, as well as gender
diﬀerences in lifestyle [39, 41]. Our results support previous
studies including a meta-analytic approach demonstrating
that most of the patients in 54 studies quantifying the
coexistence of ADs among 4 selected ADs were female [29].
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In addition, some authors have shown in specific ADs that
women are distinguished from men by higher frequencies of
concurrent immune diseases [42, 43].
AITD was the most frequent polyautoimmunity found
in our series of 1,083 patients. This finding was supported
by the analysis of the systemic literature review and depicted
in the dendogram (Figure 2) where AITD was the main
“chaperon” of autoimmunity. AITD has been described as
the most prevalent AD as well as being associated with other
organ-specific and non-organ-specific ADs [44].
Possible explanations for the relationship of these
ADs include (a) immunomodulatory eﬀects of antithyroid
antibodies, (b) molecular mimicry between thyroid and
disease-specific epitopes, and (c) a genetic link between
antithyroid autoimmunity and the susceptibility to AD [45].
In population-based database studies, other authors have
demonstrated that AITD is frequently associated with other
ADs [46]. All of this information indicates that AITD is
clinically important in the context of autoimmunity and it
is mandatory for screening patients with hypothyroidism
or hyperthyroidism symptoms for the autoimmune etiology
when there is suspicion of the coexistence of AITD with
another AD [44].
The prevalence of SS was demonstrated to be high and
in fact the second most frequently associated AD in our
series as well as in the MAS cases through the literature
review. Many authors have recognized that it is quite diﬃcult
to categorize concomitant SS as primary or secondary, and
there is disagreement about this issue in the literature [47].
Other authors believe that salivary changes in patients with
an AD (i.e., SLE) might reflect a multisystem presentation
of the disease [48]. Regarding the association of SS with
other ADs, some authors have argued that the etiopathogenic
mechanism for the simultaneous or sequential development
of multiple ADs in one individual is not well understood
[49]. The concept is more developed nowadays, and the
idea that common genetic backgrounds and additional
immunogenetic, environmental, or hormonal factors are
responsible for the formation of subsets of AD clusters is
becoming more established.
We previously evaluated the prevalence of SS in a large
series of patients with SLE (n = 969) and the potential
risk factors for this association [50]. SS patients fulfilled the
American-European classification criteria (the presence of
anti-Ro antibodies or a positive minor salivary gland biopsy
was mandatory). There were 9.3% patients with SS, 42%
had familial autoimmunity, of which 7% had familial SS
as compared to 2% in the group of SLE without SS. The
factors significantly associated with SS in SLE were familial
SS, anti-La and anti-Ro antibodies, as well as pulmonary
involvement. Anti-Sm antibodies and Colombian origin (i.e.,
ethnicity) were protective factors. Our results together with
other series [51, 52] using similar strict classification criteria
indicate that the prevalence of SS in SLE is close to 10%.
SLE-SS appears to constitute a subgroup of patients with
distinct clinical, serologic, pathologic, and immunogenetic
features, in whom SS is expressed as an associated entity
and is largely similar to what has been called primary
SS [52]. Clinical and immunological factors observed in
our study might serve as predictors for this association.
Because variations in both additive and nonadditive genetic
factors and the environmental variance are specific to the
investigated population, family history of autoimmunity and
patient origin are important characteristics to be considered.
While the currently most accepted classification criteria
[53] designate these cases as “secondary” SS, the terms
“overlapping” or “associated” SS are frequently used in the
literature to describe them [49]. We consider these terms
to be confusing and propose that SS always be taken into
account and properly investigated in patients diagnosed with
any AD because of the high possibility of the presence of
the concomitant, well-defined phenotypes as demonstrated
here in the context of polyautoimmunity or as demonstrated
previously with a prevalence near to 10% in SLE patients
when strict classification criteria are used.
It is of interest that the primary/secondary designation
for classification of APS was introduced by rheumatologists
who already used the primary/secondary terms to diﬀer-
entiate subgroups of patients with SS. In introducing the
primary APS (PAPS) subgroup, it was unclear whether one
would expect that the clinical features, disease course, or
management of patients would be diﬀerent based on their
subclassification [54]. In fact, the international (Sydney)
consensus statement on an update of the classification
criteria for definite APS [55] advises against using the term
“secondary” APS. They did not find diﬀerences in the
clinical consequences of antiphospholipid antibodies among
patients in these two categories (Evidence Level I). They state
most patients with the so-called secondary APS have SLE.
However, they discuss that it is unknown if APS and SLE
are two diseases coinciding in an individual, if underlying
SLE oﬀers a setting for the development of APS, or if APS
and SLE represent two elements of the same process [55].
Some cases with “secondary” APS are classified as lupus
like disease (LLD). The Sydney consensus raised up that
the interface between SLE, LLD, and APS merits further
consideration. Finally, the consensus states that rather than
distinguishing between patients with PAPS and secondary
APS, documenting the coexistence of SLE (or other disease)
is more advantageous for classification and that the disorder
associated with APS, such as SLE, be listed; hence, one would
report “APS associated with SLE” or “APS associated with
rheumatoid arthritis” rather than “secondary APS” [54].
Studies showing no significant diﬀerences between PAPS
and SAPS were cited. Patients with APS plus SLE and PAPS
have similar clinical profiles, although heart valve disease,
hemolytic anemia, low C4 levels, and neutropenia seem to
be more common in patients with APS plus SLE [56].
Indeed evidence that there are any diﬀerences in pre-
sentation or course of PAPS versus SAPS is not persuasive
[55, 56], and this has led to the suggestion that PAPS/SAPS
designations be replaced by APS and “APS associated with
the name of the autoimmune disease.” It might suggest
that such a distinction exists if there are diﬀerences in
clinical complications, the timing of these complications,
prognosis, or frequency of positive anticardiolipin, lupus
anticoagulant, or other autoantibody tests. Studies that have
addressed this question have found no diﬀerence in any of
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these parameters [57, 58]. As an instance, some authors have
compared intima-media thickness (IMT), arterial stiﬀness,
and presence of plaques in APS patients and controls.
A significant diﬀerence was found between IMT, arterial
stiﬀness, and the presence of plaques in patients and controls,
but no diﬀerences in these parameters were found between
patients with primary APS and those with secondary APS
[59]. Additional arguments have been raised for some
authors [60, 61] who have explored the concept of an
intermediate APS (having at least one but less than four
of the 11 criteria for SLE) and did not found diﬀerences
between PAPS, intermediate, and the so-called secondary
APS when comparing the prevalence of the thrombotic or
pregnancy manifestations.
The true prevalence of the development of PAPS in
SLE will require decades of followup for this determination.
The distinction between PAPS and SAPS can be diﬃcult
and at times seems a rather artificial convention [60]. It
may be underestimated by some studies that have a follow-
up period that is shorter than the interval between PAPS
and SLE diagnoses noted in most case reports [60]. We
agree on the proposition of the Sydney committee [55]
against using the term “secondary” APS and encourage
clinicians to follow adequately the patients and searching
for specific phenotypic characteristic to classify patients as
having polyautoimmunity.
Results with respect to the severity of the disease in
patients with polyautoimmunity are not unanimous. In the
case of associated SS, some authors have demonstrated as we
did previously [17] that there is no influence on the course
of the disease. Some have found that the appearance of SS in
RA patients has no relationship with RA duration or activity
[62]. Others demonstrated that the subset of patients with
SLE and SS has a distinct clinical and laboratory phenotype
with a lower frequency of renal disease and anti-dsDNA
antibodies [63]. This has not been true for other examples
of polyautoimmunity when there is a severe presentation of
the diseases as is the case of associated ADs in MG patients
with a severe presentation [12], a severe clinical onset of T1D
and increased prevalence of other ADs in children with CD
diagnosed before T1D [13], and a severe SLE compromise
when associated with vasculitis [14].
In conclusion, we suggest searching for well-defined
phenotypes by looking for clusters of ADs in the same
individual. It is our contention that the term “secondary
diseases” should not longer be used because it detracts
from the reality that these patients have two or more well-
established ADs sharing the same etiopathogenesis [64]. Our
results indicate that coexistence of ADs is not uncommon
and follows a grouping pattern. Polyautoimmunity is the
term proposed for this association of disorders, which
encompasses the concept of a common origin for these
diseases.
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